Loading...
•
Dec 31, 2022
PTC Therapeutics Q4 2022 Earnings Report
PTC Therapeutics reported financial results for Q4 2022 and full year ending December 31, 2022.
Key Takeaways
PTC Therapeutics reported total revenues of $167.4 million for the fourth quarter of 2022, compared to $165.2 million for the fourth quarter of 2021. The company's total revenues for the full year 2022 were $698.8 million, compared to $538.6 million for the full year 2021. PTC anticipates total revenues for the full year 2023 to be between $940 million and $1.0 billion.
Total revenues were $167.4 million for the fourth quarter of 2022.
Net product revenue across the commercial portfolio was $127.5 million for the fourth quarter of 2022.
GAAP R&D expenses were $188.7 million for the fourth quarter of 2022.
Net loss was $170.9 million for the fourth quarter of 2022.
Revenue by Segment
Forward Guidance
PTC anticipates total revenues for the full year 2023 to be between $940 million and $1.0 billion.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...